These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33399940)

  • 1. Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair.
    Ciniero G; Elmenoufy AH; Gentile F; Weinfeld M; Deriu MA; West FG; Tuszynski JA; Dumontet C; Cros-Perrial E; Jordheim LP
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):259-267. PubMed ID: 33399940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
    McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
    DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells.
    Jordheim LP; Barakat KH; Heinrich-Balard L; Matera EL; Cros-Perrial E; Bouledrak K; El Sabeh R; Perez-Pineiro R; Wishart DS; Cohen R; Tuszynski J; Dumontet C
    Mol Pharmacol; 2013 Jul; 84(1):12-24. PubMed ID: 23580445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
    Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
    Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
    Kirschner K; Melton DW
    Anticancer Res; 2010 Sep; 30(9):3223-32. PubMed ID: 20944091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
    Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
    Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
    DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and in vitro cell-free/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway.
    Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Mani RS; Ciniero G; Tuszynski JA; Weinfeld M; West FG
    Eur J Med Chem; 2020 Oct; 204():112658. PubMed ID: 32738410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy.
    Feldmann DP; Heyza J; Zimmermann CM; Patrick SM; Merkel OM
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32344513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction.
    Gentile F; Elmenoufy AH; Ciniero G; Jay D; Karimi-Busheri F; Barakat KH; Weinfeld M; West FG; Tuszynski JA
    Chem Biol Drug Des; 2020 Apr; 95(4):460-471. PubMed ID: 31891209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.
    Gentile F; Barakat KH; Tuszynski JA
    Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29710850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular docking and molecular dynamics study on the effect of ERCC1 deleterious polymorphisms in ERCC1-XPF heterodimer.
    Priya Doss CG; Nagasundaram N
    Appl Biochem Biotechnol; 2014 Feb; 172(3):1265-81. PubMed ID: 24158589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.
    McNeil EM; Melton DW
    Nucleic Acids Res; 2012 Nov; 40(20):9990-10004. PubMed ID: 22941649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.
    Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Weilbeer C; Mani RS; Barakat KH; Tuszynski JA; Weinfeld M; West FG
    J Med Chem; 2019 Sep; 62(17):7684-7696. PubMed ID: 31369707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.
    Hamilton G; Rath B
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):17-24. PubMed ID: 29226731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.
    Jordheim LP; Cros-Perrial E; Matera EL; Bouledrak K; Dumontet C
    Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):817-24. PubMed ID: 25115435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
    Ganzinelli M; Linardou H; Alvisi MF; Caiola E; Lo Russo G; Cecere FL; Bettini AC; Psyrri A; Milella M; Rulli E; Fabbri A; De Maglie M; Romanelli P; Murray S; Broggini M; Marabese M; Garassino MC
    ESMO Open; 2021 Feb; 6(1):100034. PubMed ID: 33422766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applications of genomics in NSCLC.
    Rosell R; Cobo M; Isla D; Sanchez JM; Taron M; Altavilla G; Santarpia M; Moran T; Catot S; Etxaniz O
    Lung Cancer; 2005 Dec; 50 Suppl 2():S33-40. PubMed ID: 16557672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
    Gentile F; Tuszynski JA; Barakat KH
    J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.
    Usanova S; Piée-Staffa A; Sied U; Thomale J; Schneider A; Kaina B; Köberle B
    Mol Cancer; 2010 Sep; 9():248. PubMed ID: 20846399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.